Neena Bitritto-Garg
Stock Analyst at Deutsche Bank
(2.94)
# 1,366
Out of 4,818 analysts
80
Total ratings
45.76%
Success rate
7.38%
Average return
Main Sectors:
Stocks Rated by Neena Bitritto-Garg
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACAD ACADIA Pharmaceuticals | Initiates: Hold | $22 | $14.66 | +50.07% | 16 | Feb 11, 2025 | |
| ROIV Roivant Sciences | Maintains: Buy | $14 → $15 | $10.74 | +39.66% | 5 | Apr 3, 2024 | |
| AMLX Amylyx Pharmaceuticals | Maintains: Buy | $36 → $8 | $5.09 | +57.33% | 7 | Mar 11, 2024 | |
| IMVT Immunovant | Initiates: Buy | $50 | $14.45 | +246.14% | 1 | Dec 12, 2023 | |
| NBIX Neurocrine Biosciences | Initiates: Buy | $136 | $103.25 | +31.72% | 7 | Dec 12, 2023 | |
| CMPS COMPASS Pathways | Initiates: Buy | $16 | $3.98 | +302.01% | 4 | Dec 12, 2023 | |
| PRTA Prothena Corporation | Initiates: Buy | $62 | $9.61 | +545.50% | 8 | Dec 12, 2023 | |
| ALEC Alector | Initiates: Buy | $12 | $1.17 | +925.64% | 6 | Dec 12, 2023 | |
| SAGE Sage Therapeutics | Initiates: Hold | $21 | $7.64 | +175.05% | 6 | Dec 12, 2023 | |
| SRPT Sarepta Therapeutics | Initiates: Buy | $109 | $59.44 | +83.38% | 3 | Dec 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $1.02 | +684.31% | 1 | Dec 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $10 | $1.53 | +555.74% | 4 | Jan 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $5 | $0.34 | +1,388.10% | 3 | Nov 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $6 | $3.99 | +50.56% | 5 | Aug 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $2.63 | +698.48% | 1 | Apr 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $23 | $70.87 | -67.55% | 1 | Jul 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $36 | $20.42 | +76.30% | 2 | Jul 11, 2017 |
ACADIA Pharmaceuticals
Feb 11, 2025
Initiates: Hold
Price Target: $22
Current: $14.66
Upside: +50.07%
Roivant Sciences
Apr 3, 2024
Maintains: Buy
Price Target: $14 → $15
Current: $10.74
Upside: +39.66%
Amylyx Pharmaceuticals
Mar 11, 2024
Maintains: Buy
Price Target: $36 → $8
Current: $5.09
Upside: +57.33%
Immunovant
Dec 12, 2023
Initiates: Buy
Price Target: $50
Current: $14.45
Upside: +246.14%
Neurocrine Biosciences
Dec 12, 2023
Initiates: Buy
Price Target: $136
Current: $103.25
Upside: +31.72%
COMPASS Pathways
Dec 12, 2023
Initiates: Buy
Price Target: $16
Current: $3.98
Upside: +302.01%
Prothena Corporation
Dec 12, 2023
Initiates: Buy
Price Target: $62
Current: $9.61
Upside: +545.50%
Alector
Dec 12, 2023
Initiates: Buy
Price Target: $12
Current: $1.17
Upside: +925.64%
Sage Therapeutics
Dec 12, 2023
Initiates: Hold
Price Target: $21
Current: $7.64
Upside: +175.05%
Sarepta Therapeutics
Dec 12, 2023
Initiates: Buy
Price Target: $109
Current: $59.44
Upside: +83.38%
Dec 12, 2023
Initiates: Buy
Price Target: $8
Current: $1.02
Upside: +684.31%
Jan 9, 2023
Maintains: Buy
Price Target: $20 → $10
Current: $1.53
Upside: +555.74%
Nov 11, 2022
Maintains: Buy
Price Target: $7 → $5
Current: $0.34
Upside: +1,388.10%
Aug 2, 2022
Downgrades: Sell
Price Target: $6
Current: $3.99
Upside: +50.56%
Apr 4, 2022
Initiates: Buy
Price Target: $21
Current: $2.63
Upside: +698.48%
Jul 11, 2017
Initiates: Outperform
Price Target: $23
Current: $70.87
Upside: -67.55%
Jul 11, 2017
Initiates: Outperform
Price Target: $36
Current: $20.42
Upside: +76.30%